Delivery systems and adjuvants for vaccination against HIV.
Epidemiologic studies have revealed that HIV-1 infections occur through contact with contaminated blood or during unprotected vaginal or anal intercourse. Hence, to protect against HIV infection, vaccines should induce both mucosal and systemic immune responses. We present a brief review of the different delivery systems and adjuvants which can be used to elicit mucosal immune responses. Oral or nasal administration of recombinant Salmonella vaccines can induce both mucosal and systemic immune responses against the carried antigen. The oral delivery of mucosal adjuvants (such as cholera toxin) in association with antigens has been shown to enhance mucosal and systemic immune responses against them. Recently developed vaccination strategies using naked DNA or recombinant adenovirus are also discussed.
Institute for Biochemistry, University of Lausanne, Epalinges, Switzerland.
D
D
Velin
S
S
Hopkins
J
J
Kraehenbuhl
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000284:Administration, Oral; D002772:Cholera Toxin / Q000276:immunology; D016503:Drug Delivery Systems; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology*; D012486:Salmonella typhimurium / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; D014614:Vaccines, Synthetic; D002772:Cholera Toxin